Showing 1731-1740 of 5643 results for "".
- Tangible Hydra-PEG Now Available on More Gas Permeable Contact Lenshttps://modernod.com/news/tangible-hydra-peg-now-available-on-more-gas-permeable-contact-lens/2477047/Tangible Science announced that gas permeable (GP) contact lens materials from Acuity Polymers, Bausch + Lomb, Contamac, Paragon, and SynergEyes are now available for coating with Tangible Hydra-PEG. This expanded list of approved GP lens materials compatible with Tangible Hydra-PEG means that vi
- Tangible Science and VSP Optics Co-develop New Daily Disposable Silicone Hydrogel Contact Lenshttps://modernod.com/news/tangible-science-and-vsp-optics-co-develop-new-daily-disposable-silicone-hydrogel-contact-lens/2476916/Tangible Science announced the launch of Unity BioSync contact lenses, which the company is describing as the first daily disposable silicone hydrogel contact lens featuring a modified formula of the patented Tangible Hydra-PEG polymer technology that is bonded to the surface of the lens. Co-deve
- Novartis Teams Up With Celebrity Interior Designer Nate Berkus To Launch ‘My Home In Sight’https://modernod.com/news/novartis-teams-up-with-celebrity-interior-designer-nate-berkus-to-launch-my-home-in-sight/2476753/Novartis is teaming up with celebrity interior designer Nate Berkus to launch “My Home in Sight,” a program that aims to raise awareness of the daily impact of wet age-related macular degeneration (AMD) and empower those living with wet AMD and their car
- Novartis to Acquire Dry Eye Drug Xiidra in Deal Worth Up to $5.3 Billionhttps://modernod.com/news/novartis-to-acquire-dry-eye-drug-xiidra-in-deal-worth-up-to-5-3-billion/2476567/In one of the largest ophthalmic drug deals to date, Novartis has agreed to acquire dry eye drug Xiidra (lifitegrast ophthalmic solution) 5% from Takeda Pharmaceutical in a deal worth up to $5.3 billion. Under terms of the deal, Novartis will pay $3.4 billi
- College of Optometrists in Vision Development & NORA Issue Joint Recommendation for Optometric Evaluation Following Brain Injuryhttps://modernod.com/news/college-of-optometrists-in-vision-development-nora-issue-joint-recommendation-for-optometric-evaluation-following-brain-injury/2476285/The College of Optometrists in Vision Development (COVD) and the Neuro Optometric Rehabilitation Association (NORA) issued a joint call-to-action to all healthcare professionals to consider the need for medical and/or functional optometric rehabilitation services for patients who have suffered a
- Compact Imaging Collaborates with Novartis to Accelerate Development of Home Monitor for AMD and DRhttps://modernod.com/news/compact-imaging-collaborates-with-novartis-to-accelerate-development-of-home-monitor-for-amd-and-dr/2479735/Compact Imaging (CI), a developer of miniaturized optical coherence tomography (OCT) devices, announced the signing of a collaboration agreement with Novartis Pharma under which Novartis will fund Compact Imaging’s development of a low-cost home-based monitor to detect disease progression in adva
- Eyenovia Receives Notices of Allowance from USPTO on Two Additional Patent Applications for Ophthalmic Drug Deliveryhttps://modernod.com/news/eyenovia-receives-notices-of-allowance-from-uspto-on-two-additional-patent-applications-for-ophthalmic-drug-delivery/2480109/Eyenovia announced it has received Notices of Allowance from the U.S. Patent and Trademark Office (USPTO) for two additional patent applications. The allowed patents provide fundamental coverage on physiologic microdroplet ejection diameters and velocities, which enable gentle delivery of ophthal
- New Novartis Phase 3 Data for Brolucizumab Demonstrate Reliability of 12-Week Treatment Intervalhttps://modernod.com/news/new-novartis-phase-3-data-for-brolucizumab-demonstrate-reliability-of-12-week-treatment-interval/2480190/Novartis announced new positive brolucizumab (RTH258) data in neovascular age-related macular degeneration (AMD) from a prespecified secondary analysis of the phase 3 HAWK and HARRIER trials. The findings showed that patients assessed as appropriate for a 12-week treatment frequency during
- EyePoint Pharmaceuticals Strengthens Global IP With Notices of Allowance for Two U.S. Patents Related to Dexycuhttps://modernod.com/news/eyepoint-pharmaceuticals-strengthens-global-ip-with-notices-of-allowance-for-two-u-s-patents-related-to-dexycu/2480252/EyePoint Pharmaceuticals announced that the U.S. Patent and Trademark Office (USPTO) has issued Notices of Allowance for two patents covering Dexycu, the company’s FDA-approved long-acting intraocular product for the treatment of postoperative inflammation. The first patent (U.S. patent ap
- PulseSight Therapeutics Initiates Clinical Plan of PST-611 Transferrin Vectorized Therapy for Dry AMD/GAhttps://modernod.com/news/pulsesight-therapeutics-initiates-clinical-plan-of-pst-611-transferrin-vectorized-therapy-for-dry-amdga/2482615/PulseSight Therapeutics SAS announced it has submitted a clinical trial authorization (CTA) to Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM) for a phase 1 trial (PST-611-CT1) assessing the safety